Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H9NO6 |
Molecular Weight | 191.1388 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O
InChI
InChIKey=YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19538173https://www.drugs.com/pro/sodium-nitroprusside.html |
https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2http://www.ncbi.nlm.nih.gov/pubmed/6985697https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfwww.ncbi.nlm.nih.gov/pubmed/24071762Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19538173https://www.drugs.com/pro/sodium-nitroprusside.html |
https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2http://www.ncbi.nlm.nih.gov/pubmed/6985697https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfwww.ncbi.nlm.nih.gov/pubmed/24071762
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442
Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15036360https://www.ncbi.nlm.nih.gov/pubmed/11396481
Curator's Comment: NO can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively.
Originator
Sources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19980402&CC=CA&NR=2814748A1&KC=A1https://adisinsight.springer.com/drugs/800001151http://adisinsight.springer.com/drugs/800017960https://www.ncbi.nlm.nih.gov/pubmed/14848782https://www.ncbi.nlm.nih.gov/pubmed/22040938https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/8839219http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htm
Curator's Comment: Nitroglycerin was first synthesized by the Italian chemist Ascanio Sobrero in 1847, working under Théophile-Jules Pelouze at the University of Turin
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: liberation of NO Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448 |
|||
Target ID: CHEMBL2111348 Sources: www.ncbi.nlm.nih.gov/pubmed/18574453 |
0.1 µM [EC50] | ||
Target ID: GO:0007263 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23927471 |
|||
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804 |
|||
Target ID: CHEMBL1988 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12419094 |
|||
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10553632 |
|||
Target ID: CHEMBL2111348 |
|||
Target ID: CHEMBL2111348 Sources: https://www.google.com/patents/EP2805730A1 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | NIPRIDE Approved UseSodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date1974 |
|||
Primary | NIPRIDE Approved UseSodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date1974 |
|||
Palliative | INOMAX Approved UseINOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date1999 |
|||
Primary | DILATRATE-SR Approved Usedilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1998 |
|||
Primary | MONOKET Approved Usemonoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1993 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | NITROSTAT Approved UseAcute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date2000 |
|||
Primary | NITROGLYCERIN Approved UseManagement of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date1981 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date1981 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date1981 |
|||
Primary | Metamine Approved Usehttps://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675 |
|||
Primary | PERITRATE Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
356 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
557 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1151 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.7 pg/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
15 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
29.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.89 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.03 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.26 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.08 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
32 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
37 μg/L |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 μg/L |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
32 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
34 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
8 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10 μg/L |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1458 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2524 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6979 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14241 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.3 pg × min/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
106.5 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
31.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.2 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.4 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.54 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.5 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.46 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.11 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
311 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
423 ng × h/mL |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
61 ng × h/mL |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
335 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
310 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
49 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
70 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
303 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40 min |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2 min |
single, intravenous |
NITROPRUSSIDE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12 h |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12 h |
16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.7 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.2 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6.6 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.8 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
LINSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
||
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOLSIDOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (50%) Sources: Dizziness (32%) Asthenia (14%) Nausea (10%) Bronchitis (8%) Hypotension (8%) Sinusitis (4%) Ventricular tachycardia (4%) Hyperglycemia (4%) Rhinitis (4%) Paresthesia (4%) Vomiting (4%) Amblyopia (3%) Hyperlipidemia (3%) Tachycardia (2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Disc. AE: Chest pain, Heart arrest... AEs leading to discontinuation/dose reduction: Chest pain (0.6%) Sources: Heart arrest (0.6%) Heart failure (0.6%) Hypotension (0.6%) Kidney failure (0.6%) Infection (0.4%) Ventricular fibrillation (0.4%) Dizziness (0.4%) Arrhythmia (0.2%) Cerebrovascular accident (0.2%) Syncope (0.2%) Gastroenteritis (0.2%) Myasthenia (0.2%) Dyspnea (0.2%) Edema lung (0.2%) Angioedema (0.2%) Breast carcinoma (0.2%) Uremia (0.2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Other AEs: Chest pain, Heart failure... Other AEs: Chest pain (6.4%) Sources: Heart failure (3.1%) Ventricular tachycardia (2.7%) Pneumonia (2.3%) Syncope (2.1%) Dyspnea (1.9%) Arrhythmia (1.7%) Hypotension (1.5%) Heart arrest (1.4%) Cerebrovascular accident (1.4%) Dizziness (1.4%) Cellulite (1.2%) Cerebral ischemia (1%) Coronary artery disease (1%) Anemia (1%) Bronchitis (1%) Dehydration (1%) Angina pectoris (1%) Hyperglycemia (1%) Hypoglycemia (1%) Infection (1%) Acute kidney failure (1%) Neoplasm (0.8%) Gout (0.8%) Atrial fibrillation (0.8%) Gastrointestinal hemorrhage (0.8%) Kidney failure (0.8%) Myocardial infarct (0.8%) Sepsis (0.6%) Asthma (0.6%) Accidental injury (0.6%) Cholecystitis (0.6%) Cholelithiasis (0.6%) Supraventricular tachycardia (0.6%) Esophagitis (0.4%) Edema lung (0.4%) Headache (0.4%) Osteomyelitis (0.4%) Peripheral vascular disease (0.4%) Bradycardia (0.4%) Digitalis intoxication (0.4%) Gastroenteritis (0.4%) Hyperkalemia (0.4%) Hemorrhage subarachnoid (0.4%) Deep thrombophlebitis (0.4%) Angioedema (0.4%) Ascites (0.4%) Infection (0.4%) Fibrillation ventricular (0.4%) Anomaly vascular (0.2%) Coagulation disorder (0.2%) Creatinine increased (0.2%) Hyponatremia (0.2%) Diarrhea (0.2%) Failure liver (0.2%) Neoplasm of the prostate (0.2%) Myasthenia (0.2%) Palpitations (0.2%) Urinary tract infection (0.2%) Dyspepsia (0.2%) Function kidney abnormal (0.2%) Anemia iron deficiency (0.2%) Alkalosis (0.2%) Arrhythmia nodal (0.2%) Arthralgia (0.2%) Breast carcinoma (0.2%) Hypokalemia (0.2%) Ketosis (0.2%) Cerebral infarct (0.2%) Emotional lability (0.2%) Edema face (0.2%) Gastritis hemorrhagic (0.2%) Abnormal gait (0.2%) Hematemesis (0.2%) Herpes zoster (0.2%) Uremia (0.2%) Leucopenia (0.2%) Thrombocytopenia (0.2%) Neurolysis (0.2%) Ophthalmitis (0.2%) Disorder parathyroid (0.2%) Disorder respiratory system (0.2%) Skin ulcer (0.2%) Abnormal thinking (0.2%) Vascular disorder NOS (0.2%) Wrist drop (0.2%) Gastritis (0.2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Disc. AE: Asthenia, Headache... AEs leading to discontinuation/dose reduction: Asthenia (2.3%) Sources: Headache (7.4%) Dizziness (3.7%) Pain (0.8%) Chest pain (1.5%) Nausea (1.5%) Hypotension (1.4%) Abdominal pain (0.4%) Chills (0.4%) Kidney failure (0.4%) Malaise (0.4%) Heart arrest (0.6%) Confusion (0.4%) Diarrhea (0.4%) Gastroenteritis (0.2%) Back pain (0.2%) Acute kidney failure (0.2%) Myasthenia (0.2%) Nervousness (0.2%) Pruritus (0.2%) Heart failure (0.6%) Dyspepsia (0.2%) Cerebrovascular accident (0.2%) Constipation (0.2%) Dyspnea (0.2%) Vomiting (0.6%) Paresthesia (0.6%) Function kidney abnormal (0.4%) Palpitations (0.4%) Syncope (0.4%) Rash (0.6%) Rectal hemorrhage (0.4%) Ventricular fibrillation (0.4%) Angioedema (0.2%) Amblyopia (0.2%) Anorexia (0.2%) Neck pain (0.2%) Carcinoma (0.2%) Breast carcinoma (0.2%) Dehydration (0.2%) Edema face (0.2%) Edema peripheral (0.2%) Edema lung (0.2%) Fever (0.2%) Hyperglycemia (0.2%) Hypertension (0.2%) Infection (0.2%) Fungal infection (0.2%) Impotence (0.2%) Ketosis (0.2%) Breast neoplasm (0.2%) Lab test abnormal (0.2%) Myalgia (0.2%) Photophobia (0.2%) Pleural effusion (0.2%) Somnolence (0.2%) Sweaty (0.2%) Vasodilation (0.2%) Weight decrease (0.2%) Uremia (0.2%) |
240 mg 1 times / day steady, oral Highest studied dose Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Other AEs: Headache... |
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (6 patients) Sources: |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (5%) Sources: Nausea (2%) |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Disc. AE: Rash, Pruritus... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Pruritus (2%) |
1 ug/kg/min multiple, intravenous Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (4 patients) Sources: |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 1 patient) Sources: Vomiting (severe, 1 patient) Headache (severe, 1 patient) |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Sources: |
Disc. AE: Hemodynamic test abnormal... AEs leading to discontinuation/dose reduction: Hemodynamic test abnormal (8 patients) Sources: |
0.6 mg/h 1 times / day multiple, transdermal Highest studied dose Dose: 0.6 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.6 mg/h, 1 times / day Sources: |
unhealthy, 51.4 ±4.3 years Health Status: unhealthy Age Group: 51.4 ±4.3 years Sex: F Sources: |
|
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years Health Status: unhealthy Age Group: 57 - 71 years Sex: M Sources: |
Disc. AE: Pruritic rash, Erythema edematous... AEs leading to discontinuation/dose reduction: Pruritic rash (2 patients) Sources: Erythema edematous (2 patients) Vesicular eruption (2 patients) |
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years Health Status: unhealthy Age Group: 80 years Sex: M Sources: |
Other AEs: Methemoglobinemia... Other AEs: Methemoglobinemia (grade 5, 1 patient) Sources: |
0.2 mg/h 1 times / day multiple, transdermal Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Other AEs: Headache, Lightheadedness... Other AEs: Headache (63%) Sources: Lightheadedness (6%) Hypotension (4%) Syncope (4%) |
1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension Sources: |
5 ug/kg 1 times / day single, subcutaneous Dose: 5 ug/kg, 1 times / day Route: subcutaneous Route: single Dose: 5 ug/kg, 1 times / day Sources: |
unhealthy, pediatric |
|
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Headache, Hypotension... AEs leading to discontinuation/dose reduction: Headache (0.19%) Sources: Hypotension (0.38%) Tachycardia (0.19%) |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Flushing, Headache... AEs leading to discontinuation/dose reduction: Flushing (0.75%) Sources: Headache (0.75%) Headache (grade 3, 0.75%) Hypotension (grade 3, 0.75%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 10% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Asthenia | 14% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Tachycardia | 2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Amblyopia | 3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyperlipidemia | 3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dizziness | 32% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyperglycemia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Paresthesia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Rhinitis | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Sinusitis | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ventricular tachycardia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Vomiting | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Headache | 50% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Bronchitis | 8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypotension | 8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Angioedema | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Arrhythmia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Breast carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cerebrovascular accident | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dyspnea | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema lung | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastroenteritis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Myasthenia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Syncope | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Uremia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dizziness | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Infection | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ventricular fibrillation | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Chest pain | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart arrest | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypotension | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Kidney failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Abnormal gait | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Abnormal thinking | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Alkalosis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Anemia iron deficiency | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Anomaly vascular | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Arrhythmia nodal | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Arthralgia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Breast carcinoma | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cerebral infarct | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Coagulation disorder | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Creatinine increased | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Diarrhea | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Disorder parathyroid | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Disorder respiratory system | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dyspepsia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema face | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Emotional lability | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Failure liver | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Function kidney abnormal | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastritis hemorrhagic | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastritis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hematemesis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Herpes zoster | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypokalemia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyponatremia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ketosis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Leucopenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Myasthenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Neoplasm of the prostate | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Neurolysis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ophthalmitis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Palpitations | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Skin ulcer | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Thrombocytopenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Uremia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Urinary tract infection | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Vascular disorder NOS | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Wrist drop | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Angioedema | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ascites | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Bradycardia | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Deep thrombophlebitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Digitalis intoxication | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema lung | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Esophagitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Fibrillation ventricular | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastroenteritis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Headache | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hemorrhage subarachnoid | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyperkalemia | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Infection | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Osteomyelitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Peripheral vascular disease | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Accidental injury | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Asthma | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cholecystitis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cholelithiasis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Sepsis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Supraventricular tachycardia | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Atrial fibrillation | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastrointestinal hemorrhage | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gout | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Kidney failure | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Myocardial infarct | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Neoplasm | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Acute kidney failure | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Anemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Angina pectoris | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Bronchitis | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cerebral ischemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Coronary artery disease | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dehydration | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyperglycemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypoglycemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Infection | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cellulite | 1.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cerebrovascular accident | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dizziness | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart arrest | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypotension | 1.5% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Arrhythmia | 1.7% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dyspnea | 1.9% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Syncope | 2.1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Pneumonia | 2.3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ventricular tachycardia | 2.7% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart failure | 3.1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Chest pain | 6.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Acute kidney failure | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Amblyopia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Angioedema | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Anorexia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Back pain | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Breast carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Breast neoplasm | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Cerebrovascular accident | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Constipation | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dehydration | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dyspepsia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dyspnea | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema face | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema lung | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Edema peripheral | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Fever | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Fungal infection | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Gastroenteritis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hyperglycemia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypertension | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Impotence | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Infection | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ketosis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Lab test abnormal | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Myalgia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Myasthenia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Neck pain | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Nervousness | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Photophobia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Pleural effusion | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Pruritus | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Somnolence | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Sweaty | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Uremia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Vasodilation | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Weight decrease | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Abdominal pain | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Chills | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Confusion | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Diarrhea | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Function kidney abnormal | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Kidney failure | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Malaise | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Palpitations | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Rectal hemorrhage | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Syncope | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Ventricular fibrillation | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart arrest | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Heart failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Paresthesia | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Rash | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Vomiting | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Pain | 0.8% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Hypotension | 1.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Chest pain | 1.5% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Nausea | 1.5% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Asthenia | 2.3% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Dizziness | 3.7% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Headache | 7.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, mean age 57 years Health Status: unhealthy Age Group: mean age 57 years Sex: M+F Sources: |
Headache | 57% | 240 mg 1 times / day steady, oral Highest studied dose Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Headache | 6 patients Disc. AE |
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Nausea | 2% Disc. AE |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Headache | 5% Disc. AE |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Pruritus | 2% Disc. AE |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Rash | 2% Disc. AE |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Hypotension | 4 patients Disc. AE |
1 ug/kg/min multiple, intravenous Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years |
Headache | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years |
Nausea | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years |
Vomiting | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years |
Hemodynamic test abnormal | 8 patients Disc. AE |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Sources: |
Erythema edematous | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years Health Status: unhealthy Age Group: 57 - 71 years Sex: M Sources: |
Pruritic rash | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years Health Status: unhealthy Age Group: 57 - 71 years Sex: M Sources: |
Vesicular eruption | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years Health Status: unhealthy Age Group: 57 - 71 years Sex: M Sources: |
Methemoglobinemia | grade 5, 1 patient | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years Health Status: unhealthy Age Group: 80 years Sex: M Sources: |
Hypotension | 4% | 0.2 mg/h 1 times / day multiple, transdermal Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Syncope | 4% | 0.2 mg/h 1 times / day multiple, transdermal Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Lightheadedness | 6% | 0.2 mg/h 1 times / day multiple, transdermal Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Headache | 63% | 0.2 mg/h 1 times / day multiple, transdermal Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Hypotension | Disc. AE | 1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 0.19% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Tachycardia | 0.19% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Hypotension | 0.38% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Flushing | 0.75% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Headache | 0.75% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Headache | grade 3, 0.75% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Hypotension | grade 3, 0.75% Disc. AE |
16 mg 1 times / day multiple, oral Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: multiple Dose: 16 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Page: abstract |
no | |||
Sources: https://link.springer.com/article/10.1007/BF00497774 Page: abstract |
yes | |||
Page: abstract |
yes | |||
Page: abstract |
yes | |||
Sources: https://www.nature.com/articles/aps201225 Page: abstract |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of alterations of arterial blood pressure and heart rate on segmental dyskinesis during acute myocardial ischemia and following coronary reperfusion. | 1975 Jan |
|
Venodilator effects of adenosine triphosphate and sodium nitroprusside; comparisons during controlled hypotension. | 1987 Sep 1 |
|
[Nitric oxide dependence of the anti-thrombotic effect of sydnonimines in coronary arteries of swine]. | 1991 |
|
Comparative cardiovascular effects of SNP, ATP and phentolamine during norepinephrine-induced hypertension in dogs. | 1991 Oct |
|
CAS 936, a novel syndnonimine with direct vasodilating and nitric oxide-donating properties: effects on isolated blood vessels. | 1991 Oct |
|
Baroreflex changes produced by serotonergic or catecholaminergic lesions in the rat nucleus tractus solitarius. | 1992 Apr |
|
Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs. | 1992 Sep 10 |
|
Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3754, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure. | 1993 |
|
Effects of nitric oxide-containing compounds on increases in cytosolic ionized Ca2+ and on aggregation of human platelets. | 1993 Jan 4 |
|
Nitric oxide controls cardiac substrate utilization in the conscious dog. | 1999 Nov |
|
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors. | 1999 Oct 15 |
|
[Reactivity of cerebral vessels in patients with circulatory encephalopathy, arterial hypertension and cerebral hypoperfusion risk]. | 2001 |
|
Glyceryl trinitrate and acute uterine relaxation: a literature review. | 2001 Apr |
|
Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom. | 2001 Apr |
|
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. | 2001 Apr |
|
NO-dependent vasorelaxation is impaired after gene transfer of inducible NO-synthase. | 2001 Aug |
|
Improved analysis of brachial artery ultrasound using a novel edge-detection software system. | 2001 Aug |
|
Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. | 2001 Aug 31 |
|
[Aspirin and nitroglycerine: a good combination for gastric mucosa]. | 2001 Aug-Sep |
|
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). | 2001 Feb |
|
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report. | 2001 Feb |
|
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. | 2001 Feb |
|
NO donors inhibit Leishmania infantum cysteine proteinase activity. | 2001 Feb 9 |
|
Impaired vasodilator response to organic nitrates in isolated basilar arteries. | 2001 Jan |
|
Sodium nitroprusside compared with isoflurane-induced hypotension: the effects on brain oxygenation and arteriovenous shunting. | 2001 Jul |
|
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. | 2001 Jul |
|
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope. | 2001 Jul |
|
Gender difference in age-related changes in vascular function. | 2001 Jul |
|
Transoesophageal acoustic quantification for evaluation of cardiac function during laparoscopic surgery. | 2001 Jul |
|
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control. | 2001 Jul |
|
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes. | 2001 Jun |
|
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. | 2001 Jun |
|
Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. | 2001 Mar |
|
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction. | 2001 Mar 12 |
|
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. | 2001 May |
|
An update on nesiritide for treatment of decompensated heart failure. | 2001 May |
|
Glyceryl trinitrate ointment as a potential treatment for primary vaginismus. | 2001 May |
|
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. | 2001 May 1 |
|
[Nitrate headache in blasting work]. | 2001 May 15 |
|
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial. | 2001 May-Jun |
|
Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. | 2001 Sep 14 |
|
Acute sympathoexcitatory action of angiotensin II in conscious baroreceptor-denervated rats. | 2002 Aug |
|
Myocardial tissue oxygen during coronary artery constriction and hypotension in dogs. | 2002 Jul |
|
Internal thoracic artery flow competition: studies in a canine H-graft model. | 2003 Jan |
|
Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. | 2004 Dec 15 |
|
The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. | 2004 Nov 5 |
|
Regulation of cytoplasmic stress granules by apoptosis-inducing factor. | 2004 Sep 1 |
|
Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. | 2005 Jan |
|
Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes. | 2005 Mar |
|
NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. | 2006 Aug 17 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20962031
mice were treated three times a week for 3 weeks with intravenous tail vein injections of either vehicle (2.25% Pluronic P123 in PBS) or JS-K (6 μmol/kg in the vehicle).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28653883
Curator's Comment: In epithelial cells, NO increased apoptosis by 2.1 +/- 0.2-fold, augmented mRNA expression of Bax, and reduced expression of Bcl-2 compared with basal cultures. In stromal cells, NO increased cell proliferation in a dose-dependent manner, an effect that was blocked by a NO synthase inhibitor.
Human U87 cells (HTB-14), fibroblasts (CRL-1634), and astrocytes (CRL-8621; ATCC) were cultured in Dulbecco’s Minimal Essential Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal calf serum (FCS) and penicillin (100U/mL)/streptomycin (100mg/mL) under normoxic conditions (95% air, 5% CO2, and 37°C). The nitric oxide donor JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen-1-ium1,2-diolate, CAS 7054 32-12-8) was dissolved in 100% dimethyl sulfoxide (DMSO) in a concentration of 5.2mM. U87 was incubated with JS-K doses of 0–15µM for 4 h. The JS-K solvent control (DMSO≤1%) was adjusted to the highest JS-K concentration used in these experiments. A cesium source emitting γ-radiation was used for radiotherapy (RT; 3×2Gy) with a 24-h interval between each RT dose (Isotopen Diagnostik CIS, Germany).
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000009909
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NDF-RT |
N0000007647
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
WHO-ATC |
C01DA14
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NDF-RT |
N0000007647
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NDF-RT |
N0000175415
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NDF-RT |
N0000007647
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
NDF-RT |
N0000007647
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
||
|
WHO-VATC |
QC01DA14
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
240-197-2
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
Z-57
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
6062
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
1353102
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
28004
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
758619
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
100000090392
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
5177
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
LX1OH63030
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
m6541
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB08336MIG
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
LX1OH63030
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
C030397
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
SUB30087
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
27661
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
C47575
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
DB01020
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
1506
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
ISOSORBIDE MONONITRATE
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
DTXSID9023176
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
16051-77-7
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
SUB12087MIG
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
ALTERNATIVE | |||
|
CHEMBL1311
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY | |||
|
7052
Created by
admin on Mon Mar 31 17:55:59 GMT 2025 , Edited by admin on Mon Mar 31 17:55:59 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD